MonTa Biosciences announced completion of a Series A investment from existing investor Consolidated Biosciences Aps of 40 mDKK to secure completion of a phase I study in cancer patients. The study will test the lead asset of MonTa Biosciences MBS8, which is a promising immunotherapy to boost the immune system of cancer patients using a unique technology to activate the patients immune system. MBS8 is a nanoparticle consisting of a small molecule compound of the TLR7 class formulated in micelles, and is administered by the intravenous route to activate immune cells of the patient. The phase I trial will enroll patients with solid tumors and be conducted in Denmark and Spain.
